Intervention Review

Auranofin versus placebo in rheumatoid arthritis

  1. Maria E Suarez-Almazor1,*,
  2. Carol Spooner2,
  3. Elaine Belseck3,
  4. Beverley Shea4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 24 APR 2000

Assessed as up-to-date: 21 FEB 2000

DOI: 10.1002/14651858.CD002048


How to Cite

Suarez-Almazor ME, Spooner C, Belseck E, Shea B. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002048. DOI: 10.1002/14651858.CD002048.

Author Information

  1. 1

    The University of Texas, M.D. Anderson Cancer Center, General Internal Medicine, Ambulatory Treatment and Emergency Care, Houston, Texas, USA

  2. 2

    1G1.52 Walter Mackenzie Health Centre, Division of Emergency Medicine, Edmonton, Alberta, Canada

  3. 3

    University of Alberta, Department of Pediatrics, Alberta, Canada

  4. 4

    University of Ottawa, Institute of Population Health, Ottawa, Ontario, Canada

*Maria E Suarez-Almazor, General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 437, Houston, Texas, 77030, USA. msalmazor@mdanderson.org.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 APR 2000

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andrea Savarino, Iart Luca Shytaj, Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS, Retrovirology, 2015, 12, 1

    CrossRef

  2. 2
    Tanya Doan, Elena Massarotti, Rheumatoid Arthritis: An Overview of New and Emerging Therapies, The Journal of Clinical Pharmacology, 2005, 45, 7